title: In Patients with Type 2 Diabetes and CV Disease, Empagliflozin Reduces CV and All-Cause Mortality.
authors.affiliation: University of Georgia, Athens, GA, USA.
authors.forename: Mark H
authors.initials: MH
authors.lastname: Ebell
mesh_terms: D001559:Benzhydryl Compounds / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000209:etiology / Q000401:mortality / Q000517:prevention & control*; D002423:Cause of Death / Q000639:trends; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy*; D014943:Global Health; D005960:Glucosides / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D015996:Survival Rate / Q000639:trends
chemical_list: D001559:Benzhydryl Compounds; D005960:Glucosides; D007004:Hypoglycemic Agents; C570240:empagliflozin